I'm the author of Airpocalypse, a medical thriller

Welcome to the digital era of biology (and to this modest blog I started in early 2005).

To cure many diseases, like cancer or cystic fibrosis, we will need to target genes (mutations, for ex.), not organs! I am convinced that the future of replacement medicine (organ transplant) is genomics (the science of the human genome). In 10 years we will be replacing (modifying) genes; not organs!

Anticipating the $100 genome era and the P4™ medicine revolution. P4 Medicine (Predictive, Personalized, Preventive, & Participatory): Catalyzing a Revolution from Reactive to Proactive Medicine.

I am an early adopter of scientific MOOCs. I've earned myself four MIT digital diplomas: 7.00x, 7.28x1, 7.28.x2 and 7QBWx. Instructor of 7.00x: Eric Lander PhD.

Upcoming books: Airpocalypse, a medical thriller (action taking place in Beijing) 2017; Jesus CRISPR Superstar, a sci-fi -- French title: La Passion du CRISPR (2018).

I love Genomics. Would you rather donate your data, or... your vital organs? Imagine all the people sharing their data...

Audio files on this blog are Windows files ; if you have a Mac, you might want to use VLC (http://www.videolan.org) to read them.

Concernant les fichiers son ou audio (audio files) sur ce blog : ce sont des fichiers Windows ; pour les lire sur Mac, il faut les ouvrir avec VLC (http://www.videolan.org).

New York Genome Center Announcing A Partnership With IBM -- Bringing Watson To Genomics

"The deal is essentially a test run. The NYGC will use Watson to try to help oncologists tailor specific drug regimens to individual patients with glioblastoma—an aggressive form of brain cancer that typically kills people 12 to 14 months after they’re diagnosed—based on the specific genetic mutations in each patient’s tumor. The goal is to use this process to improve the standard of care for glioblastoma patients, and then expand the NYGC/Watson effort into other types of cancer. Bloom says nine hospitals and 20 neurologists, all in New York, are on board so far, but that the NYGC isn’t limiting the effort to any particular hospitals.
Here’s how the process is expected to work. Once a patient is diagnosed with glioblastoma, the NYGC will get a tumor sample. Researchers there will sequence the tumor’s genome, and analyze it to come up with a set of mutations that look like the 'drivers' for that specific patient’s tumor, Bloom says. Researchers will then feed that list of mutations into Watson, which will do all of the computational dirty work to find a list of drugs that would target them specifically.
Watson’s job will be 'to do the literature search, the drug database search, and find all the relationships between those specific mutations and drugs that are available or maybe in clinical trials that they can find, or even drugs that are related to the pathways that those mutations are associated with,' Bloom says.
From there, a team of neurologists and pharmacologists will look over the list of drugs that Watson generates, pick a set of them that they think would best work together, and recommend those to the patient’s doctor. Should the patient decide to follow the recommended regimen, the NYGC will track his condition, the rate at which the tumors spread, etc.—and then start feeding that information back into Watson.
'So we’ll be giving Watson back information about combinations of mutations, combinations of drugs, and the outcomes of using those drugs on those mutations,' Bloom says. 'That’s a very complex set of associations, and we’re hoping that Watson, and Watson’s learning model, can then find information in that that we can not see so fast.'
The study hasn’t started as of yet, but the hope is that as more patients start undergoing treatment, and more data is fed to Watson, the computer will find things researchers wouldn’t, and 'we can iterate more quickly and improve care more quickly,' Bloom says. Assuming the lists Watson produces leads to treatment regimens that helps patients keep tumors in check longer, and live longer—which has yet to be seen—the project would then expand. Presumably, Watson would also be used by other genome centers as well (the NYGC does not have an exclusive license).
'There are 1,700 glioblastoma patients in NY every year,' Bloom says. 'So there’s a lot to be done in New York.'" (Source).

Understanding the biology of the disease:

Aucun commentaire: